IL126902A - Tetrahydrolipstatin containing compositions - Google Patents

Tetrahydrolipstatin containing compositions

Info

Publication number: IL126902A
Authority: IL; Israel
Prior art keywords: weight; composition; pellets; polyvinylpyrrolidone; tetrahydrolipstatin
Prior art date: 1997-02-05

Application number

IL12690298A

Other languages

English (en)

Other versions

IL126902A0 (en

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-02-05

Filing date

1998-01-24

Publication date

2002-12-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26671373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL126902(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-01-24 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

1999-09-22 Publication of IL126902A0 publication Critical patent/IL126902A0/xx

2002-12-01 Publication of IL126902A publication Critical patent/IL126902A/en

Links

AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 title claims abstract description 35
229960001243 orlistat Drugs 0.000 title claims abstract description 10
AHLBNYSZXLDEJQ-UHFFFAOYSA-N N-formyl-L-leucylester Natural products CCCCCCCCCCCC(OC(=O)C(CC(C)C)NC=O)CC1OC(=O)C1CCCCCC AHLBNYSZXLDEJQ-UHFFFAOYSA-N 0.000 title claims abstract description 9
239000000203 mixture Substances 0.000 title claims description 33
239000008188 pellet Substances 0.000 claims abstract description 44
239000002245 particle Substances 0.000 claims abstract description 26
229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 16
239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 16
229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 16
235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 16
239000003381 stabilizer Substances 0.000 claims abstract description 16
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 13
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 22
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 22
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 20
239000008109 sodium starch glycolate Substances 0.000 claims description 12
229940079832 sodium starch glycolate Drugs 0.000 claims description 12
229920003109 sodium starch glycolate Polymers 0.000 claims description 12
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 11
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 11
239000002552 dosage form Substances 0.000 claims description 9
239000008187 granular material Substances 0.000 claims description 9
239000000454 talc Substances 0.000 claims description 8
229910052623 talc Inorganic materials 0.000 claims description 8
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
239000008101 lactose Substances 0.000 claims description 7
239000003085 diluting agent Substances 0.000 claims description 5
239000007884 disintegrant Substances 0.000 claims description 5
239000004094 surface-active agent Substances 0.000 claims description 4
229920002261 Corn starch Polymers 0.000 claims description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
229930006000 Sucrose Natural products 0.000 claims description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
239000008120 corn starch Substances 0.000 claims description 2
235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 2
YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 claims description 2
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
239000005720 sucrose Substances 0.000 claims description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims 1
229910052708 sodium Inorganic materials 0.000 claims 1
239000011734 sodium Substances 0.000 claims 1
239000000463 material Substances 0.000 description 7
239000000243 solution Substances 0.000 description 7
238000009472 formulation Methods 0.000 description 6
239000000843 powder Substances 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 5
238000000034 method Methods 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
235000010980 cellulose Nutrition 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
-1 for example Substances 0.000 description 4
239000007903 gelatin capsule Substances 0.000 description 4
238000005469 granulation Methods 0.000 description 4
238000005563 spheronization Methods 0.000 description 4
239000003826 tablet Substances 0.000 description 4
239000011230 binding agent Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 3
238000007906 compression Methods 0.000 description 3
230000006835 compression Effects 0.000 description 3
238000005538 encapsulation Methods 0.000 description 3
230000003179 granulation Effects 0.000 description 3
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
241000275031 Nica Species 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
239000007910 chewable tablet Substances 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000001035 drying Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000001125 extrusion Methods 0.000 description 2
230000003301 hydrolyzing effect Effects 0.000 description 2
238000004898 kneading Methods 0.000 description 2
229940069328 povidone Drugs 0.000 description 2
235000020183 skimmed milk Nutrition 0.000 description 2
239000012798 spherical particle Substances 0.000 description 2
238000009736 wetting Methods 0.000 description 2
229940122816 Amylase inhibitor Drugs 0.000 description 1
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
102000004366 Glucosidases Human genes 0.000 description 1
108010056771 Glucosidases Proteins 0.000 description 1
229940086609 Lipase inhibitor Drugs 0.000 description 1
102000019280 Pancreatic lipases Human genes 0.000 description 1
108050006759 Pancreatic lipases Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
239000003392 amylase inhibitor Substances 0.000 description 1
230000003579 anti-obesity Effects 0.000 description 1
239000000883 anti-obesity agent Substances 0.000 description 1
229940125710 antiobesity agent Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000001752 chlorophylls and chlorophyllins Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
229940043264 dodecyl sulfate Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
229940116369 pancreatic lipase Drugs 0.000 description 1
235000011837 pasties Nutrition 0.000 description 1
238000005453 pelletization Methods 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000007873 sieving Methods 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000009987 spinning Methods 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
238000010977 unit operation Methods 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Diabetes (AREA)
Obesity (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Biophysics (AREA)
Child & Adolescent Psychology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL12690298A 1997-02-05 1998-01-24 Tetrahydrolipstatin containing compositions IL126902A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US3738497P	1997-02-05	1997-02-05
US09/003,137 US6004996A (en)	1997-02-05	1998-01-06	Tetrahydrolipstatin containing compositions
PCT/EP1998/000395 WO1998034607A1 (en)	1997-02-05	1998-01-24	Tetrahydrolipstatin containing compositions

Publications (2)

Publication Number	Publication Date
IL126902A0 IL126902A0 (en)	1999-09-22
IL126902A true IL126902A (en)	2002-12-01

Family

ID=26671373

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL12690298A IL126902A (en)	1997-02-05	1998-01-24	Tetrahydrolipstatin containing compositions

Country Status (29)

Country	Link
US (1)	US6004996A (de)
EP (1)	EP0921796B1 (de)
CN (1)	CN1193752C (de)
AR (1)	AR010704A1 (de)
AT (1)	ATE200027T1 (de)
AU (1)	AU713192B2 (de)
CA (1)	CA2258095C (de)
CO (1)	CO4920214A1 (de)
CY (1)	CY2264B1 (de)
CZ (1)	CZ287154B6 (de)
DE (1)	DE69800639T2 (de)
DK (1)	DK0921796T3 (de)
ES (1)	ES2156028T3 (de)
GR (1)	GR3036064T3 (de)
HR (1)	HRP980057B1 (de)
HU (1)	HU225035B1 (de)
ID (1)	ID26509A (de)
IL (1)	IL126902A (de)
MA (1)	MA24466A1 (de)
MY (1)	MY118371A (de)
NO (1)	NO320445B1 (de)
NZ (1)	NZ332659A (de)
PE (1)	PE57599A1 (de)
PT (1)	PT921796E (de)
RU (1)	RU2170579C2 (de)
SI (1)	SI0921796T1 (de)
UY (1)	UY24875A1 (de)
WO (1)	WO1998034607A1 (de)
YU (1)	YU49423B (de)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2201272C2 (ru) *	1997-02-05	2003-03-27	Ф.Хоффманн-Ля Рош Аг	Применение ингибиторов желудочно-кишечной липазы
CA2340056C (en) *	1998-08-14	2007-01-09	F. Hoffmann-La Roche Ag	Pharmaceutical compositions containing lipase inhibitors
EP1112063A4 (de) *	1998-09-08	2009-05-13	Smithkline Beecham Corp	Tabletten auf der grundlage eines lpstatinderivates und löslicher fasern
AR025587A1 (es) *	1999-09-13	2002-12-04	Hoffmann La Roche	Formulaciones en dispersion que contienen inhibidores de lipasa
AR025609A1 (es) *	1999-09-13	2002-12-04	Hoffmann La Roche	Formulaciones lipidas solidas
EP1132389A1 (de)	2000-03-06	2001-09-12	Vernalis Research Limited	Neue Azaindolyl-Derivate für die Behandlung von Fettleibigheit
DE10021618A1 (de) *	2000-05-04	2001-11-15	Volker Helmstaedter	Präparat für Darmerkrankungen und dessen Verwendung
PT1296656E (pt) *	2000-06-27	2006-12-29	Hoffmann La Roche	Processo para a preparação de uma composição
CZ302087B6 (cs) *	2000-07-28	2010-10-06	F. Hoffmann-La Roche Ag	Farmaceutický prípravek obsahující orlistat spolu se sekvestrantem žlucových kyselin pro použití pro lécení a prevenci obezity
EP1307263B1 (de)	2000-07-28	2005-04-20	F. Hoffmann-La Roche Ag	Neue verwendung von lipase-inhibitoren
CN1323661C (zh)	2000-08-09	2007-07-04	霍夫曼-拉罗奇有限公司	脂酶抑制剂的用途
US6900226B2 (en)	2000-09-06	2005-05-31	Hoffman-La Roche Inc.	Neuropeptide Y antagonists
WO2002044152A1 (en)	2000-10-16	2002-06-06	F. Hoffmann-La Roche Ag	Indoline derivatives and their use as 5-ht2 receptor ligands
GB0030710D0 (en) *	2000-12-15	2001-01-31	Hoffmann La Roche	Piperazine derivatives
CN1250549C (zh)	2000-12-27	2006-04-12	霍夫曼-拉罗奇有限公司	吲哚衍生物及其作为5－ht2b和5－ht2c受体配体的应用
GB0106177D0 (en) *	2001-03-13	2001-05-02	Hoffmann La Roche	Piperazine derivatives
AU2002338896B2 (en)	2001-05-21	2006-04-27	F.Hoffman-La Roche Ag	Quinoline derivatives as ligands for the neuropeptide Y receptor
US20030027786A1 (en) *	2001-06-06	2003-02-06	Karsten Maeder	Lipase inhibiting composition
US6787558B2 (en) *	2001-09-28	2004-09-07	Hoffmann-La Roche Inc.	Quinoline derivatives
US7357891B2 (en)	2001-10-12	2008-04-15	Monosol Rx, Llc	Process for making an ingestible film
US8900498B2 (en)	2001-10-12	2014-12-02	Monosol Rx, Llc	Process for manufacturing a resulting multi-layer pharmaceutical film
US10285910B2 (en)	2001-10-12	2019-05-14	Aquestive Therapeutics, Inc.	Sublingual and buccal film compositions
US20110033542A1 (en)	2009-08-07	2011-02-10	Monosol Rx, Llc	Sublingual and buccal film compositions
US20070281003A1 (en)	2001-10-12	2007-12-06	Fuisz Richard C	Polymer-Based Films and Drug Delivery Systems Made Therefrom
US20190328679A1 (en)	2001-10-12	2019-10-31	Aquestive Therapeutics, Inc.	Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8765167B2 (en)	2001-10-12	2014-07-01	Monosol Rx, Llc	Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8603514B2 (en)	2002-04-11	2013-12-10	Monosol Rx, Llc	Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US11207805B2 (en)	2001-10-12	2021-12-28	Aquestive Therapeutics, Inc.	Process for manufacturing a resulting pharmaceutical film
US8900497B2 (en)	2001-10-12	2014-12-02	Monosol Rx, Llc	Process for making a film having a substantially uniform distribution of components
DE10152351B4 (de) *	2001-10-18	2005-09-22	Schering Ag	Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
JP3624954B1 (ja) *	2001-11-07	2005-03-02	藤沢薬品工業株式会社	分散不良薬物の溶出性を改善する方法
DE60213283T2 (de) *	2001-12-20	2007-07-12	Alpex Pharma S.A.	Pharmazeutische zusammensetzung enthaltend magermilchpulver
GB0202015D0 (en) *	2002-01-29	2002-03-13	Hoffmann La Roche	Piperazine Derivatives
KR100659428B1 (ko) *	2002-02-04	2006-12-19	에프. 호프만-라 로슈 아게	Ｎｐｙ 길항제로서의 퀴놀린 유도체
KR100611854B1 (ko)	2002-02-28	2006-08-11	에프. 호프만-라 로슈 아게	신경 펩타이드 ｙ(ｎｐｙ) 수용체 길항제로서의 티아졸유도체
WO2003090742A1 (en) *	2002-04-26	2003-11-06	F. Hoffmann-La Roche Ag	Pharmaceutical composition comprising a lipase inhibitor and glucomannan
EP1560816A1 (de) *	2002-07-05	2005-08-10	F. Hoffmann-La Roche Ag	Chinazoline derivate
EP1539722A1 (de) *	2002-08-07	2005-06-15	F. Hoffmann-La Roche Ag	Thiazolderivate
EP1539746B1 (de) *	2002-09-12	2006-11-15	F. Hoffmann-La Roche Ag	N-substituierte-1h-indol-5-propansäure verbindungen als ppar-agonisten zur behandlung von diabetis
MXPA05005445A (es) *	2002-11-25	2005-08-26	Hoffmann La Roche	Derivados de indolilo.
US20040178058A1 (en) *	2003-03-10	2004-09-16	Hsueh-Chung Chen	Electro-chemical deposition apparatus and method of preventing cavities in an ECD copper film
GB0314967D0 (en) *	2003-06-26	2003-07-30	Hoffmann La Roche	Piperazine derivatives
WO2005014593A1 (en) *	2003-08-12	2005-02-17	F. Hoffmann-La Roche Ag	Thiazole derivatives as npy antagonists
WO2005014592A1 (en) *	2003-08-12	2005-02-17	F. Hoffmann-La Roche Ag	2-amino-5-benzoylthiazole npy antagonists
US20060246141A1 (en) *	2005-04-12	2006-11-02	Elan Pharma International, Limited	Nanoparticulate lipase inhibitor formulations
KR100895758B1 (ko) *	2005-05-03	2009-04-30	에프. 호프만-라 로슈 아게	5-ｈｔ2 리간드로서 테트라사이클릭 아자피라지노인돌린
KR100910000B1 (ko) *	2005-05-13	2009-07-29	씨제이제일제당 (주)	리파아제 저해제 함유 약학 조성물
PL1897558T3 (pl) *	2005-06-09	2014-01-31	Norgine Bv	Stały preparat 2-heksadecyloksy-6-metylo-4H-3,1-benzoksazyn-4-onu
JP2009504707A (ja) *	2005-08-18	2009-02-05	エフ．ホフマン−ラロシュアーゲー	Ｈ３受容体調節剤として有用なチアゾリルピペリジン誘導体
WO2007041643A1 (en) *	2005-10-03	2007-04-12	University Of Tennessee Research Foundation	Dietary calcium for reducing the production of reactive oxygen species
ATE466007T1 (de) *	2005-11-30	2010-05-15	Hoffmann La Roche	5-substituierte indol-2-carbonsäureamidderivate
EP1968967B1 (de) *	2005-11-30	2011-04-27	F. Hoffmann-La Roche AG	1,1-dioxo-thiomorpholinyl-indolyl-methanon-derivate zur verwendung als h3-modulatoren
BRPI0619268A2 (pt) *	2005-11-30	2011-09-20	Hoffmann La Roche	compostos, processo para a sua manufatura, composições farmacêuticas, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, uso dos compostos e método para o tratamento ou prevenção de obesidade e de diabetes do tipo ii em um ser humano ou animal
US7579351B2 (en) *	2005-12-09	2009-08-25	Hoffmann-La Roche Inc.	Tricyclic amide derivatives
ES2334580T3 (es) *	2005-12-15	2010-03-12	F. Hoffmann-La Roche Ag	Derivados de pirrolo(2,3-c)piridina.
AU2006326067A1 (en) *	2005-12-16	2007-06-21	F. Hoffmann-La Roche Ag	Pyrrolo [2 , 3-b] pyridine derivatives as H3 receptor modulators
EP1803714A1 (de) *	2005-12-27	2007-07-04	KRKA, tovarna zdravil, d.d., Novo mesto	Verfahren zur Herstellung kristalliner Formen von Orlistat
BRPI0707916A2 (pt) *	2006-01-13	2011-05-17	Hoffmann La Roche	compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem e uso destes compostos
ES2349160T3 (es) *	2006-01-23	2010-12-28	F. Hoffmann-La Roche Ag	Derivados de la ciclohexil sulfonamida con actividad frente a los receptores h3.
US7432255B2 (en) *	2006-05-16	2008-10-07	Hoffmann-La Roche Inc.	1H-indol-5-yl-piperazin-1-yl-methanone derivatives
AU2007267184A1 (en) *	2006-05-30	2007-12-06	F. Hoffmann-La Roche Ag	Piperidinyl pyrimidine derivatives
EP1872777A1 (de) *	2006-06-27	2008-01-02	LEK Pharmaceuticals D.D.	Pharmazeutische Zusammensetzung enthaltend Tetrahydrolipstatin
US7514433B2 (en)	2006-08-03	2009-04-07	Hoffmann-La Roche Inc.	1H-indole-6-yl-piperazin-1-yl-methanone derivatives
US20080146559A1 (en)	2006-12-08	2008-06-19	Li Chen	4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives
TR200607613A2 (tr) *	2006-12-29	2008-07-21	NOBEL İLAÇ SAN.ve TiC.A.Ş.	Lipaz inhibitörü içeren farmasötik formülasyonlar
SI2002825T1 (sl) *	2007-06-14	2013-10-30	Krka	Farmacevtski sestavki, ki obsegajo orlistat
WO2009039157A2 (en) *	2007-09-17	2009-03-26	Dr. Reddy's Laboratories Ltd.	Orlistat pharmaceutical formulations
WO2009044380A2 (en)	2007-10-05	2009-04-09	Ranbaxy Laboratories Limited	Formulations containing orlistat particles having controlled particle size
EP2219614A1 (de) *	2007-10-15	2010-08-25	Inventis DDS Pvt Limited	Pharmazeutische zusammensetzung von orlistat
US8298583B2 (en)	2007-10-19	2012-10-30	Monosol Rx, Llc	Film delivery system for tetrahydrolipstatin
US20090220593A1 (en) *	2008-01-29	2009-09-03	Gulati Inder	Extended release dosage forms of quetiapine
PL216542B1 (pl)	2008-03-20	2014-04-30	Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna	Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
US8309107B2 (en) *	2008-10-06	2012-11-13	Banner Pharmacaps, Inc.	Stable solutions of orlistat for pharmaceutical dosage forms
BRPI0901602B8 (pt) *	2009-04-03	2021-05-25	Ems S/A	formulação farmacêuticas
MX342962B (es)	2009-09-18	2016-06-07	Teva Pharmaceuticals Holdings Mexico S A De C V	Composicion farmaceutica para bajar de peso y procedimiento para obtener la misma.
UA107369C2 (en) *	2010-02-01	2014-12-25	Lab Bago S A	Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process
RU2441654C2 (ru) *	2010-02-17	2012-02-10	Лабораториос Баго С.А.	Фармацевтическая композиция с активностью против ожирения, включающая премикс чистого орлистата, и способ ее изготовления
US20120040008A1 (en)	2010-08-11	2012-02-16	Ashish Chatterji	Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120039999A1 (en)	2010-08-11	2012-02-16	Ashish Chatterji	Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US9149959B2 (en)	2010-10-22	2015-10-06	Monosol Rx, Llc	Manufacturing of small film strips
EP2720723B1 (de) *	2011-06-15	2018-04-11	Synthon BV	Stabilisierte voriconazolzusammensetzung
PH12014500198A1 (en)	2011-07-15	2017-02-10	Nusirt Sciences Inc	Compositions and methods for modulating metabolic pathways
CN102362863B (zh) *	2011-11-21	2013-06-12	山东新时代药业有限公司	一种含奥利司他的制剂及其制备方法
WO2013092786A1 (en)	2011-12-23	2013-06-27	Norgine B.V.	Compositions comprising cetilistat
GB201122213D0 (en) *	2011-12-23	2012-02-01	Norgine Bv	Compositions
AU2012101841A4 (en) *	2011-12-23	2013-01-17	Norgine Bv	Compositions comprising cetilistat
US9198454B2 (en)	2012-03-08	2015-12-01	Nusirt Sciences, Inc.	Compositions, methods, and kits for regulating energy metabolism
IN2014MN01933A (de) *	2012-03-13	2015-07-10	Piramal Entpr Ltd
JP6469015B2 (ja)	2012-11-13	2019-02-13	ニューサートサイエンシーズ，インコーポレイテッド	エネルギー代謝を増大させるための組成物および方法
DE202012104963U1 (de)	2012-12-19	2013-01-14	Norgine B.V.	Cetilistat aufweisende Zusammensetzungen
US9585876B2 (en)	2013-03-15	2017-03-07	Nusirt Sciences, Inc.	Leucine and nicotinic acid reduces lipid levels
CN104740637A (zh) *	2013-12-31	2015-07-01	北京科信必成医药科技发展有限公司	一种稳定的奥利司他口服制剂及其制备方法
JP2017506651A (ja)	2014-02-27	2017-03-09	ニューサートサイエンシーズ，インコーポレイテッド	脂肪肝の低減または予防のための組成物および方法
US10743813B2 (en)	2014-09-11	2020-08-18	Rattan Nath	Diabetes control using postprandial feedback
US12433850B2 (en)	2016-05-05	2025-10-07	Aquestive Therapeutics, Inc.	Enhanced delivery epinephrine and prodrug compositions
US11273131B2 (en)	2016-05-05	2022-03-15	Aquestive Therapeutics, Inc.	Pharmaceutical compositions with enhanced permeation
US12427121B2 (en)	2016-05-05	2025-09-30	Aquestive Therapeutics, Inc.	Enhanced delivery epinephrine compositions
JP7653218B2 (ja)	2016-05-05	2025-03-28	アクエスティブセラピューティクスインコーポレイテッド	送達増強エピネフリン組成物
CN108785272B (zh) *	2018-09-04	2019-04-09	中山万汉制药有限公司	一种奥利司他软胶囊及其制备方法
CN115105476B (zh) *	2021-03-23	2023-11-14	山东新时代药业有限公司	一种奥利司他冻干口服制剂及其制备工艺
US12465564B2 (en)	2021-10-25	2025-11-11	Aquestive Therapeutics, Inc.	Oral and nasal compositions and methods of treatment
CN115300479A (zh) *	2022-08-23	2022-11-08	宁波高新区美诺华医药创新研究院有限公司	奥利司他胶囊制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1247547A (en) *	1983-06-22	1988-12-28	Paul Hadvary	Leucine derivatives
JPH04198129A (ja) *	1990-11-28	1992-07-17	Sumitomo Pharmaceut Co Ltd	活性型ビタミンｄ↓３類含有組成物
CA2098167C (en) *	1992-06-24	2006-12-19	Dorothea Isler	Foodstuffs and feedstuffs containing a lipase inhibitor
TW381025B (en) *	1993-08-05	2000-02-01	Hoffmann La Roche	Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor

1998
- 1998-01-06 US US09/003,137 patent/US6004996A/en not_active Expired - Lifetime
- 1998-01-24 CZ CZ19983528A patent/CZ287154B6/cs not_active IP Right Cessation
- 1998-01-24 DK DK98905346T patent/DK0921796T3/da active
- 1998-01-24 NZ NZ332659A patent/NZ332659A/xx not_active IP Right Cessation
- 1998-01-24 PT PT98905346T patent/PT921796E/pt unknown
- 1998-01-24 SI SI9830023T patent/SI0921796T1/xx unknown
- 1998-01-24 RU RU98120492/14A patent/RU2170579C2/ru active
- 1998-01-24 YU YU49698A patent/YU49423B/sh unknown
- 1998-01-24 CN CNB988003694A patent/CN1193752C/zh not_active Expired - Lifetime
- 1998-01-24 HU HU0001468A patent/HU225035B1/hu unknown
- 1998-01-24 ES ES98905346T patent/ES2156028T3/es not_active Expired - Lifetime
- 1998-01-24 IL IL12690298A patent/IL126902A/en not_active IP Right Cessation
- 1998-01-24 AT AT98905346T patent/ATE200027T1/de active
- 1998-01-24 CA CA002258095A patent/CA2258095C/en not_active Expired - Lifetime
- 1998-01-24 DE DE69800639T patent/DE69800639T2/de not_active Expired - Lifetime
- 1998-01-24 ID IDW980113D patent/ID26509A/id unknown
- 1998-01-24 EP EP98905346A patent/EP0921796B1/de not_active Expired - Lifetime
- 1998-01-24 AU AU60972/98A patent/AU713192B2/en not_active Expired
- 1998-01-24 WO PCT/EP1998/000395 patent/WO1998034607A1/en not_active Ceased
- 1998-02-02 PE PE1998000070A patent/PE57599A1/es not_active IP Right Cessation
- 1998-02-03 AR ARP980100472A patent/AR010704A1/es unknown
- 1998-02-03 MY MYPI98000418A patent/MY118371A/en unknown
- 1998-02-04 UY UY24875A patent/UY24875A1/es not_active IP Right Cessation
- 1998-02-04 CO CO98005480A patent/CO4920214A1/es unknown
- 1998-02-04 HR HR980057A patent/HRP980057B1/xx not_active IP Right Cessation
- 1998-02-05 MA MA24956A patent/MA24466A1/fr unknown
- 1998-11-16 NO NO19985337A patent/NO320445B1/no not_active IP Right Cessation
2001
- 2001-06-18 GR GR20010400907T patent/GR3036064T3/el unknown
2002
- 2002-04-05 CY CY0200014A patent/CY2264B1/xx unknown

Also Published As

Publication number	Publication date
US6004996A (en)	1999-12-21
IL126902A0 (en)	1999-09-22
YU49698A (sh)	1999-09-27
HUP0001468A3 (en)	2000-12-28
HRP980057B1 (en)	2001-08-31
AU6097298A (en)	1998-08-26
RU2170579C2 (ru)	2001-07-20
DK0921796T3 (da)	2001-07-16
YU49423B (sh)	2006-01-16
HK1021313A1 (en)	2000-06-09
NZ332659A (en)	2000-03-27
CY2264B1 (en)	2003-07-04
AU713192B2 (en)	1999-11-25
ATE200027T1 (de)	2001-04-15
CA2258095A1 (en)	1998-08-13
PL330972A1 (en)	1999-06-21
NO320445B1 (no)	2005-12-05
HRP980057A2 (en)	1998-12-31
AR010704A1 (es)	2000-06-28
ES2156028T3 (es)	2001-06-01
DE69800639D1 (de)	2001-05-03
CN1220600A (zh)	1999-06-23
CA2258095C (en)	2000-02-22
HU0001468D0 (en)	2000-05-28
EP0921796B1 (de)	2001-03-28
MA24466A1 (fr)	1998-10-01
DE69800639T2 (de)	2001-10-31
GR3036064T3 (en)	2001-09-28
NO985337D0 (no)	1998-11-16
PE57599A1 (es)	1999-06-11
HUP0001468A2 (hu)	2000-09-28
PT921796E (pt)	2001-09-28
CZ287154B6 (en)	2000-09-13
HU225035B1 (en)	2006-05-29
SI0921796T1 (en)	2001-06-30
WO1998034607A1 (en)	1998-08-13
ID26509A (id)	2001-01-11
MY118371A (en)	2004-10-30
CN1193752C (zh)	2005-03-23
CO4920214A1 (es)	2000-05-29
UY24875A1 (es)	2000-12-29
EP0921796A1 (de)	1999-06-16
CZ352898A3 (cs)	1999-02-17
NO985337L (no)	1998-11-16

Legal Events

Date	Code	Title
2003-05-29	FF	Patent granted
2003-06-24	FF	Patent granted
2003-06-24	KB	Patent renewed
2004-02-19	KB	Patent renewed
2008-02-10	KB	Patent renewed
2012-01-31	KB	Patent renewed
2016-01-31	KB	Patent renewed
2018-08-30	EXP	Patent expired

Publication	Publication Date	Title
AU713192B2 (en)	1999-11-25	Tetrahydrolipstatin containing compositions
KR100365572B1 (ko)	2003-07-02	서방성조성물및약학조성물의제조방법
KR100563342B1 (ko)	2006-03-22	맛이 차단된 약학 조성물
US6063313A (en)	2000-05-16	Process for the preparation of fine particle pharmaceutical formulations
KR101141508B1 (ko)	2012-05-04	판토프라졸 복합 미립자 제형
US6368622B2 (en)	2002-04-09	Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
AU764280B2 (en)	2003-08-14	Process for the preparation of pellets with a content of up to 90 wt. per cent of a pharmaceutical active ingredient
EP1256338B1 (de)	2004-05-12	Verfahren zur Herstellung von Formulierungen zur Direkttablettierung
UA82268C2 (uk)	2008-03-25	Гранули, що містять гідрохлорид венлафаксину, та спосіб їх виготовлення
WO1995018602A1 (en)	1995-07-13	ORAL DOSAGE FORM OF DESMOPRESSIN (dDAVP)
CZ20032138A3 (cs)	2005-03-16	Způsoby a prostředky pro zeslabení chuti farmaceuticky aktivních činidel
Goskonda et al.	1994	Development of matrix controlled release beads by extrusion-spheronization technology using a statistical screening design
JP3059149B2 (ja)	2000-07-04	テトラヒドロリプスタチン含有組成物
MXPA98009224A (en)	1999-09-01	Tetrahydrolipstatin containing compositions
JP5134818B2 (ja)	2013-01-30	脂質制御薬物製剤の製造のための方法
HK1021313B (en)	2005-06-10	Tetrahydrolipstatin containing compositions
TW533082B (en)	2003-05-21	Tetrahydrolipstatin containing compositions
PL203578B1 (pl)	2009-10-30	Kompozycja farmaceutyczna
SA98190009B1 (ar)	2006-02-11	تركيبات متوية على رابع هيدروليبستاتين tetrahydrolipstatin
BG62316B1 (bg)	1999-08-31	фармацевтични форми с постоянно освобождаване и метод за получаването им